General American Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

General American Investors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-45,000	Closed	-$3.08M	–	78
2021 Q1	$3.08M	Hold	45,000	–	–	0.29%	61
2020 Q4	$3.86M	Hold	45,000	–	–	0.38%	55
2020 Q3	$2.92M	Hold	45,000	–	–	0.34%	53
2020 Q2	$3.29M	Sell	45,000 -20,000	-31%	-$1.06M	0.42%	55
2020 Q1	$2.21M	Buy	+65,000	New	+$2.97M	0.3%	53

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

General American Investors's BHVN Position: Q2 2021 in Review

General American Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 45,000 shares — an estimated $3.08M sold.

General American Investors first reported a position in BHVN in Q1 2020 and held it in 5 quarters. The position peaked at $3.86M in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

General American Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
General American Investors sold 45,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $3.08M.
General American Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 5 quarters.
General American Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.86M in Q4 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on General American Investors's 13F filing for Q2 2021, filed 5 Aug 2021.